Tools
Stock profile

IONIS PHARMACEUTICALS INC (IONS)

IONS · Latest close $27.39 as of Nov 18, 2026 · 13F data as of Jun 30, 2026 (2026 Q2)
Latest close
$27.39
As of Nov 18, 2026
Tracked funds holding
5 of 149
2026 Q2 13F filings
Opened / added
0 / 3
vs previous quarter
Trimmed / exited
0
vs previous quarter

IONIS PHARMACEUTICALS INC (IONS) is held by 5 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 3 funds adding versus the previous quarter. Insiders were net buyers over the last 90 days ($148.2K bought vs $61.4K sold). Latest close $27.39 as of Nov 18, 2026.

Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: Nov 10, 2026 · Congress to Nov 16, 2026.

Funds
2026 Q2 13F
Insiders · 90d
net $86.8K
Fundamentals
Revenue · FY2025
Red flags
none flagged
Short interest
as of Oct 15, 2026
Holdings · Charts · All institutions · Fundamentals · Short interest · Fails to deliver · Insider trading · 5% holders · Planned sales · Politician trading · Committee jurisdiction · Government relations · Screens & lenses · Signal record · Related stocks · Recent 8-K

Funds holding this

Tweedy Browne · Deep Track Capital · Deerfield Management — 5 tracked funds hold IONS. See all holders.

Insider and Congress activity

Insiders bought on the open market (1 purchase, $148.2K) vs 2 sales ($61.4K). Latest buy: Nov 10, 2026. Insider trading

Often held alongside

AVALYN PHARMA INC (AVLN) · NURIX THERAPEUTICS INC (NRIX) · Celcuity Inc. (CELC) · COGENT BIOSCIENCES INC (COGT) · DYNE THERAPEUTICS INC (DYN) — stocks the same funds also hold. See all related stocks.

Super-investor holdings · 2026 Q2

FundPortfolio weightSharesChange vs prev. quarter
Tweedy Browne13.70%2,280,311ADDED (+0.2%) Q3 filed Nov 4
Deep Track Capital2.54%2,200,000ADDED (+12.8%) Q3 filed Nov 16
Deerfield Management1.64%1,979,669HELD Q3 filed Nov 16
Baker Bros. Advisors0.81%2,047,727HELD Q3 filed Nov 16
Perceptive Advisors0.67%566,000ADDED (+12.3%) Q3 filed Nov 16

Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.

Price change since quarter-end: -66.0% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.

Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.

Charts

86.5023.072024-11-192026-11-18

Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.

All institutions · Form 13F

Institutions holding518 of 8,857 filers
Long-only filers among them511
Change vs 2026 Q1+31 net · 485 entered · 454 exited
Shares reported, all filers179,686,810
Reported value, all filers$14.1B

Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).

Company fundamentals

ExchangeNasdaq
IndustryPharmaceutical Preparations (SIC 2834)
Revenue · FY2025$943.7M
Net income · FY2025$-381.4M
Total assets · FY2025$3.5B
Shares outstanding166,184,322
Market cap (at latest close)$4.6B

Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Jul 23, 2026.

Short interest

Shares short · Oct 15, 202620,653,026
Share of shares outstanding12.43%
Days to cover7.65

Shares short at recent settlements — Jul 31, 2026: 21.5M · Aug 14, 2026: 20.9M · Aug 31, 2026: 20.9M · Sep 15, 2026: 20.9M · Sep 30, 2026: 22.5M · Oct 15, 2026: 20.7M.

Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Jul 23, 2026.

Fails to deliver

Shares failed to deliver · Oct 14, 20260
Share of shares outstanding0.00%
Fails as a share of short interest · Oct 15, 20260.0%

Fails to deliver at recent settlements — Jul 31, 2026: 0 · Aug 14, 2026: 200 · Aug 31, 2026: 0 · Sep 15, 2026: 0 · Sep 30, 2026: 0 · Oct 14, 2026: 0.

Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Jul 23, 2026.

Insider trading · Form 4

1 insider bought on the open market in the last 90 days (1 purchase, $148.2K), against 2 sales by 2 insiders ($61.4K). Latest buy: Nov 10, 2026.

Source: SEC Form 4 filings. Open-market transactions only.

Latest open-market buyTransaction pricePrice change since disclosure
Hayden Michael R · 5,000 shares on Nov 10, 2026 · filed Nov 13, 2026$29.64-3.8% (close Nov 16, 2026 → Nov 17, 2026)

Reference close is the first trading day after the filing (Nov 16, 2026). The transaction price is what the insider paid; the price change is on closing prices (dividends excluded).

Recent open-market trades

DateInsiderRoleBuy / SellSharesPriceValueSource
Nov 10, 2026Hayden Michael RBuy5,000$29.64$148.2KSEC filing
Oct 16, 2026Devers Shannon L.EVP, Chief Human Resources OfcSell1,357$43.54$59.1KSEC filing
Oct 16, 2026Swayze EricEVP ResearchSell53$43.54$2.3KSEC filing

Most recent open-market transactions in the same 90-day window, most recent first. Source: SEC Form 4 filings.

Planned sales · Form 144

FiledSellerRoleShares to sellMarket valueApprox. sale dateSource
Jul 7, 2026Diaz Allene M.Director10,111$863.6KJul 7, 2026SEC filing
Jul 7, 2026Kordasiewicz Holly B.Officer1,287$108.5KJul 7, 2026SEC filing
Jul 7, 2026BENNETT C FRANKOfficer67,386$5.7MJul 7, 2026SEC filing
Jul 1, 2026KLEIN JOSEPH IIIDirector11,518$910.4KJul 1, 2026SEC filing
Jun 26, 2026Baroldi MarianaMember of immediate family of any of the foregoing5,635$451.7KJun 26, 2026SEC filing
Jun 26, 2026O'NEIL PATRICK R.Officer3,069$245.5KJun 26, 2026SEC filing
Jun 26, 2026Schneider EugeneOfficer47,884$3.9MJun 26, 2026SEC filing
Jun 25, 2026Swayze EricOfficer10,602$839.3KJun 25, 2026SEC filing
Jun 15, 2026BERTHELSEN SPENCER RDirector8,000$587.9KJun 15, 2026SEC filing
Jun 12, 2026Kordasiewicz Holly B.Officer60,846$4.5MJun 12, 2026SEC filing

A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.

5% holders · Schedule 13D/G

FiledFilerFormShares% ownedEvent dateSource
May 15, 2026T. Rowe Price Investment Management, Inc.SC 13G/A6,159,0273.7%Mar 31, 2026SEC filing
May 14, 2026Capital World InvestorsSC 13G/A21,186,36912.8%Mar 31, 2026SEC filing
Apr 30, 2026Vanguard Capital ManagementSC 13G8,344,7325.0%Mar 31, 2026SEC filing
Mar 27, 2026The Vanguard GroupSC 13G/A00.0%Mar 13, 2026SEC filing
Feb 17, 2026T. Rowe Price Investment Management, Inc.SC 13G/A9,108,0195.6%Dec 31, 2025SEC filing
Jan 7, 2026Capital World InvestorsSC 13G/A17,961,29911.1%Dec 31, 2025SEC filing
Nov 14, 2025T. Rowe Price Investment Management, Inc.SC 13G/A13,157,1148.3%Sep 30, 2025SEC filing
Aug 12, 2025Wellington Management Group LLPSC 13G/A6,879,8734.3%Jun 30, 2025SEC filing
Apr 17, 2025BlackRock, Inc.SC 13G/A9,066,5175.7%Mar 31, 2025SEC filing
Feb 13, 2025Capital World InvestorsSC 13G11,465,4137.3%Dec 31, 2024SEC filing

One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.

Politician trading · U.S. Congress

Data unavailable — no congressional STOCK Act transactions for this ticker were parsed in the current window (as of Nov 16, 2026).

Committee jurisdiction

Industry: Pharmaceutical Preparations (SIC 2834). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.

None of the members who traded this stock in the current window sit on these committees.

Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.

Government relations

Lobbying: 18 Lobbying Disclosure Act filings named this company as client, 2024–2026; most common issues: Health Issues (18), Medicare/Medicaid (9), Taxation/Internal Revenue Code (8).

Federal contracts: no obligated amounts found for this ticker (USASpending, fiscal years 2021–2026).

Lobbying filings are matched by company core name; a filing can match more than one ticker. Contract amounts are obligated amounts (money committed, not money spent), matched by recipient name — contracts under a subsidiary’s name can be missed. Sources: Senate Lobbying Disclosure Act filings; USAspending.gov. See Methodology.

Screens & lenses

This stock does not currently pass any tracked screen.

Also held by the tracked funds that hold IONS — ranked by lift, the co-holding pattern described in Methodology: AVALYN PHARMA INC (AVLN) · NURIX THERAPEUTICS INC (NRIX) · Celcuity Inc. (CELC) · COGENT BIOSCIENCES INC (COGT) · DYNE THERAPEUTICS INC (DYN) · Immunovant, Inc. (IMVT) · Mirum Pharmaceuticals, Inc. (MIRM) · Praxis Precision Medicines, Inc. (PRAX).

Recent 8-K filings

FiledItemsSource
Nov 9, 20262.02 Results of Operations and Financial Condition · 9.01 Financial Statements and ExhibitsSEC filing
Oct 23, 20267.01 Regulation FD Disclosure · 8.01 Other Events · 9.01 Financial Statements and ExhibitsSEC filing
Oct 21, 20267.01 Regulation FD Disclosure · 8.01 Other Events · 9.01 Financial Statements and ExhibitsSEC filing

Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.

Related

AVALYN PHARMA INC (AVLN) · Track Record: how the signals scored · Practice timing on IONS

One email a week: the week’s new filings and research. Subscribe free

← IONQ  ·  IOT →

Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.